

JOURNAL OF HEPATOLOGY

ABSTRACT BOOK

THE INTERNATIONAL
LIVER CONGRESS™

APRIL 10 - 14, VIENNA, AUSTRIA

2019

SEE YOU NEXT YEAR IN
LONDON – 15-19 APRIL 2020

JOURNAL OF HEPATOLOGY

VOLUME **70**, SUPPLEMENT **1S**, PAGES **e1–e952**

Abstracts of The International Liver Congress™ 2019 – 54th annual
meeting of the European Association for the Study of the Liver
April 10–14, 2019, Vienna, Austria

Publication of this abstract supplement was supported by the European Association for the Study of the Liver

ELSEVIER

JOURNAL OF HEPATOLOGY

VOLUME 70, SUPPLEMENT 1S, PAGES e1–e952

CONTENTS

Acknowledgements.....	iv
Thursday, 11 April 2019	
General session I and opening ceremony	e1
NAFLD Pathophysiology – Target identification	e5
Autoimmune and cholestasis I	e9
Portal Hypertension – Refining risk stratification and therapy	e13
Liver disease immunology	e19
Mechanism of regeneration response to injury	e23
Liver tumours – Experimental	e26
Hepatitis B/D/E – Clinical aspects	e30
NAFLD – Clinical burden natural history	e35
Cascade of care towards elimination of viral hepatitis	e39
Friday, 12 April 2019	
General session II and award ceremony I	e45
Hepatitis B – drug development	e48
Cirrhosis – Clinical aspects	e52
Liver fibrosis	e56
Acute and acute-on-chronic liver failure Translational aspects	e62
NAFLD – Clinical Therapy	e67
Liver cancer – From Prognosis to locoregional treatments	e71
Autoimmune and cholestasis II	e75
Saturday, 13 April 2019	
General session III and award ceremony II	e81
NAFLD – Preclinical pipeline	e84
Liver cancer – Systemic treatment and immunotherapy	e87
Cirrhosis – Experimental aspects	e91
Translational virology	e95
Gut-Liver Axis	e98
Liver transplantation I	e102
Alcohol related liver disease	e107
Hepatitis C – Treatment and resistance	e110
Non-invasive assessment of liver disease	e114
Clinical developments in rare liver disease	e118

Flash abstract: HBV and Pregnancy	e123
Late breaker: Orals	e127
Sunday, 14 April 2019	
NAFLD – Staging and prognosis	e133
Liver transplantation II	e137
Posters Thursday, 11 April 2019	
Late breaker: Posters	e141
Autoimmune and chronic cholestatic liver disease: Experimental and pathophysiology	e161
Cirrhosis: ACLF and Critical illness	e173
Fibrosis	e187
Viral hepatitis C: Therapy and resistance	e207
Viral hepatitis B/D: Clinical aspects except therapy	e252
Alcoholic liver disease	e273
NAFLD: Clinical aspects except therapy	e288
Imaging and drug targeting	e313
Liver development, physiology and regeneration	e317
Public Health	e322
Liver tumours: Experimental and pathophysiology	e352
Posters Friday, 12 April 2019	
Autoimmune and chronic cholestatic liver disease: Clinical aspects	e383
Acute liver failure and drug induced liver injury	e418
Cirrhosis and its complications: Experimental and pathophysiology	e433
Viral Hepatitis A, B, C, D, E: Immunology	e445
Viral hepatitis B/D: therapy	e457
Viral hepatitis C: Clinical aspects except therapy	e491
Gut microbiota and liver disease	e510
NAFLD: Experimental and pathophysiology	e518
Liver transplantation and hepatobiliary surgery: Clinical aspects	e553
Nurses' research in Hepatology	e573
Rare liver diseases (including pediatric and genetic)	e579
Liver tumours: Therapy	e594
Posters Saturday, 13 April 2019	
Cirrhosis and its complications: Clinical	e625
Viral Hepatitis A, B, C, D, E: Virology	e699
Viral hepatitis A/E: Clinical aspects	e719
Viral Hepatitis C: Post SVR and long term follow up	e725
NAFLD: Diagnostics and non-invasive assessment	e753
NAFLD: Therapy	e787
Immunology except viral hepatitis	e798
Molecular and cellular biology	e803
Non-invasive assessment of liver disease except NAFLD	e814
Liver transplantation and hepatobiliary surgery: Experimental	e829
Liver tumours: Clinical aspects except therapy	e831

Author Index	e855
Disclosures: no commercial relationships	e935
Disclosures: commercial relationships	e943

Registration of Clinical Trials

The *Journal of Hepatology* endorses the policy of the WHO and the International Committee of Medical Journal Editors (ICMJE) on the registration of clinical trials. Therefore, any trial that starts recruiting on or after July 1, 2005 should be registered in a publicly owned, publicly accessible registry and should satisfy a minimal standard dataset. Trials that started recruiting before that date will be considered for publication if registered before September 13, 2005.

More detailed information regarding clinical trials and registration can be found in *New Engl J Med* 2004; 351:1250–1251 and *New Engl J Med* 2005; 352:2437–2438.

Available online at www.sciencedirect.com



ScienceDirect

for online access via your library

the presence of high risk varices (HRV), defined as grade II, III esophageal and gastric varices, in patients with compensated liver cirrhosis. The **aim** of the study was to determinate the utility of spleen stiffness (SS) values measured by 2D-SWE as non-invasive marker for prediction of HRV, in patients with compensated liver cirrhosis.

Method: A prospective study was performed in 55 subjects with compensated liver cirrhosis, who underwent both spleen stiffness measurements (SSM) with a 2D-SWE technique (General Electric LOGIQ E9 XD clear 2.0) and upper endoscopy in the same admission. Spleen stiffness was performed with the patient in supine position and the SWE evaluation box was placed in the middle of the spleen, avoiding large vessels. Reliable SSM were defined as the median value of 10 measurements acquired in a homogenous area and an interquartile range/median (IQR/M) <0.30. Compensated liver cirrhosis was diagnosed based on clinical, biological and elastographic criteria (FibroScan > 12, 5 kPa)

Results: We obtained reliable SSM in 53/55 subjects (96.4%). 28/55 (51%) subjects had HRV. The mean SS values for patients with HRV were significantly higher as compared to those with first grade or no varices (18.6 ± 4.3 kPa vs. 15.7 ± 2.8 kPa with p = 0.0056). The best SS cut-off value measured with 2D-SWE-GE for predicting the presence of HRV in our study group was: 17.2 kPa (AUROC-0.80; sensitivity-67.8%; specificity-92%; PPV-91%; NPV-71, 9%).

Conclusion: Using the SS cut-off value > 17.2 kPa obtained by means of 2D-SWE we can rule in the presence of HRV, with a positive predictive value of 91%.

THU-076

SPP1 gene knockout in human hepatic stellate cells decreased profibrogenic cytokines and collagen gene expression

Joseph George¹, Takashi Saito¹, Nobuhiko Hayashi¹, Kazuaki Ozaki¹, Mikihiro Tsutsumi¹, Mutsumi Tsuchishima¹. ¹Kanazawa Medical University, Hepatology, Uchinada, Japan
Email: georgej@kanazawa-med.ac.jp

Background and aims: Secreted phosphoprotein-1 (SPP1) is a stress sensitive multifunctional cytokine involved in innate immunity, cell proliferation, invasion, and metastasis. It was observed that SPP1 promotes activation and transformation of resting hepatic stellate cells into myofibroblast like cells and drives collagen synthesis. The purpose of the study was to evaluate the role of SPP1 on activation and transformation of human hepatic stellate cells and subsequent production of profibrogenic cytokines and collagen gene expression.

Method: Primary human hepatic stellate cells were isolated from pieces of surgically resected human liver tissue after pronase and collagenase digestion and purified using density gradient centrifugation. The isolated and purified stellate cells were cultured with appropriate medium for 48 h. The cultures were then divided into two sets and one set was treated with SPP1 CRISPR guide RNA sequences that efficiently knockout SPP1 gene without significant binding of Cas9 elsewhere in the genome. The second set of cultures without SPP1 CRISPR gRNA treatment served as control. The cultures were maintained for another 7–10 days. The cells were fixed and stained for α -smooth muscle actin (α -SMA) to examine the activation of stellate cells. Western blotting was carried out for SPP1, PDGF-B, TGF- β 1, and collagens type I and type III. qPCR was performed to quantify mRNA of α -SMA, and collagens type I and type III.

Results: Immunocytochemical staining showed that the isolated quiescent stellate cells were positive for glial fibrillary acidic protein (GFAP) and negative for α -smooth muscle actin (α -SMA). Western blotting demonstrated complete knockout of SPP1 after treatment with CRISPR/Cas9 gRNA. Knockdown of SPP1 in primary hepatic stellate cells prevented activation and transformation of over 50% hepatic stellate cells into myofibroblast like cells and depicted marked decrease in the staining intensity of α -SMA. Western blotting for PDGF-B, TGF- β 1, and collagens type I and type III showed

significant decrease in the protein levels in SPP1 knockout cells. qPCR demonstrated marked reduction in the expression of α -SMA and collagens type I and type III mRNA indicating decreased activation of stellate cells and reduced synthesis of collagens after deletion of SPP1 gene.

Conclusion: The results of the present study demonstrated that SPP1 regulates profibrogenic cytokines and activation of stellate cells contributing to the pathogenesis of hepatic fibrosis. Furthermore, blocking of SPP1 has potential therapeutic implications to arrest hepatic fibrosis and related events.

THU-077

Fibro-protective molecular and cellular mechanisms emerge during resolution from thioacetamide-induced fibrosis

Francis Gratte^{1,2}, Jully Gogoi-Tiwari², Xiao Liu^{3,4}, Tatiana Kisseleva⁴, David Brenner³, John Olynyk^{1,5,6}, Janina Tirmitz-Parker^{2,7}. ¹Murdoch University, School of Veterinary and Life Science, Perth, Australia; ²Curtin University, School of Pharmacy and Biomedical Sciences, Curtin Health Innovation Research Institute, Perth, Australia; ³University of California San Diego, School of Medicine, La Jolla, United States; ⁴University of California San Diego, Department of Surgery, La Jolla, United States; ⁵Fiona Stanley Hospital, Murdoch, Australia; ⁶Edith Cowan University (ECU), School of Medical and Health Sciences, Mount Lawley, Australia; ⁷The University of Western Australia, School of Medicine and Pharmacology, Perth, Australia
Email: francis.gratte@curtin.edu.au

Background and aims: The reported dynamic nature of hepatic stellate cells (HSCs) during fibrosis and resolution highlights that little is known of the fate of their co-migratory partner, liver progenitor cells (LPCs). Manipulating the known co-regulatory relationship between LPCs and HSCs during specific phases of fibrosis to alter their dynamic phenotypes may represent a new therapeutic target. Here we investigate thioacetamide (TAA) pre-treatment and recovery in mice, and the role and mechanism of resulting cell populations in the fibro-dynamic microenvironment of the liver after reintroduction of TAA.

Method: Tissue and sera were collected from C57BL/6 mice of two study groups (n = 5–9 per group): (a) pre-treated; 6-week TAA (300 mg/L drinking water), 4-week recovery, 6-week TAA and (b) naïve; 10-week control diet and 6-week TAA. Liver injury and fibrosis was characterized by extensive biochemical, histological and transcriptional analysis. Inflammatory, LPC and HSC subpopulations were identified by immunofluorescent staining. Primary isolated HSCs from healthy, fibrotic, and recovering mouse liver were co-cultured with the clonal bipotential murine oval liver (BMOL) LPC line prior to qPCR analysis of fibrotic transcriptional regulation.

Results: Phenotypically distinct inactivated desmin⁺, α SMA⁻, GFAP⁻ HSCs and CK19⁺ LPCs were confirmed in livers of pre-treated mice at d0, but not in naïve mice by immunofluorescence. TAA treatment induced early CD45⁺ inflammatory cell proliferation in naïve mice typical to this model, which was notably absent in pre-treated mice. Elevated serum ALT levels and profibrogenic (α SMA, TGF β 1, Col1A1 and TIMP1) transcription during early TAA treatment indicated a severe damage response in naïve mice. Incomplete resolution of fibrosis in pre-treated mice remained static throughout subsequent treatment, whereas naïve mice progressed to cirrhosis after 6 weeks of TAA. Primary HSCs isolated from fibrotic mice exhibit significantly reduced α SMA, Col1A1 and TGF β 1 expression after co-culture with BMOL progenitor cells, suggesting anti-fibrotic regulation of HSCs through LPCs in this setting.

Conclusion: Contrary to the carbon tetrachloride model used in other recovery studies, TAA pre-treatment stimulates compensatory mechanisms, moderating the effects of a subsequent hepatic insult. As revealed through direct HSC-LPC coculture, LPCs may play a role in anti-fibrotic regulation of HSCs and could represent a mechanistic key to stabilising fibrosis for therapeutic benefit in patients with recurrent fibrotic pathology.